Japanese Record-Breaking Anime Blockbuster Film EVANGELION:3.0+1.01 THRICE UPON A TIME to Launch Exclusively on Amazon Prime Video on August 13th
1.7.2021 18:35:00 EEST | Business Wire | Press release
Amazon Prime Video today announced the exclusive global premiere (outside of Japan) of the highly anticipated Japanese anime blockbuster EVANGELION:3.0+1.01 THRICE UPON A TIME on August 13th. EVANGELION:3.0+1.01 THRICE UPON A TIME is the fourth and final chapter of the new theatrical edition of Evangelion. The anime film – which is the highest-grossing in all movies by chief director Hideaki Anno and most-watched movie in Japanese theatres in 2021- is from directors Kazuya Tsurumaki, Katsuichi Nakayama and Mahiro Maeda as well as legendary creator, screenwriter and chief director Hideaki Anno (Shin Godzilla). To celebrate the finale of the franchise, Prime Video will also release the three previous movies, EVANGELION:1.11 YOU ARE (NOT) ALONE., EVANGELION:2.22 YOU CAN (NOT) ADVANCE., EVANGELION:3.33 YOU CAN (NOT) REDO. to fans in more than 240 countries and territories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005692/en/
Japanese Record-Breaking Anime Blockbuster Film EVANGELION:3.0+1.01 THRICE UPON A TIME to Launch Exclusively on Amazon Prime Video on August 13th (Graphic: Business Wire)
The blockbuster franchise is a Japanese anime pop culture phenomenon based on the story of Evangelion, an artificial human and multipurpose humanoid weapon, and the Angels, an unknown life-form which takes place after the Earth has been shattered by a cataclysmic event. The film features all original voice actors including Megumi Ogata, Megumi Hayashibara, Yûko Miyamura and uses the latest imaging technology to showcase the personalities and relationships of its unique characters as they fight for survival. It will be dubbed in 10 languages including English, French, German, Portuguese, Spanish and Italian, and offer subtitles in 28 languages.
Since the TV series first aired in 1995, the Evangelion franchise has had a significant impact on Japanese pop culture and has elevated the anime genre worldwide. The legendary anime franchise was then reborn as a new movie series Evangelion: New Theatrical Edition in 2007 and this fourth and final movie released across theatres in Japan in March has gone on to break records, both for Hideaki Anno’s films and also as Japan’s most-watched theatrical movie of the year. EVANGELION:3.0+1.01 THRICE UPON A TIME on Amazon Prime Video will be the latest version of the film which includes revised scenes and is releasing across theatres now in Japan.
“The EVANGELION films have been thrilling fans for years and we know that there is a huge appetite around the world for the finale,” said Brad Beale, Vice President, Worldwide Content Licensing Prime Video. “I’m excited for Prime members worldwide to finally have the opportunity to watch the anime masterpiece EVANGELION:3.0+1.01 THRICE UPON A TIME, as well as the three previous films.”
“I’d like to thank every Eva fan in the world for your continued support,” said Hideaki Anno, Creator, Screenwriter and Chief Director. “We were looking for the best way to offer the movie to fans overseas as early as possible in a challenging situation with movie theatres during COVID-19, and are happy to have found Prime Video as a partner to stream it globally. We highly recommend watching it on a big TV screen for the best viewing experience.”
ABOUT
EVANGELION:3.0+1.01 THRICE UPON A TIME
The fourth and final installment of the Rebuild of Evangelion. Misato and her anti-Nerv group Wille arrive in Paris, a city now red from core-ization. Crew from the flagship Wunder land on a containment tower. They only have 720 seconds to restore the city. When a horde of Nerv Evas appear, Mari’s improved Eva Unit 8 must intercept. Meanwhile, Shinji, Asuka, and Rei (provisional name) wander around Japan.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Kazuya Tsurumaki, Katsuichi Nakayama and Mahiro Maeda, Screenwriter: Hideaki Anno
ABOUT THE THREE PREVIOUS MOVIES
EVANGELION:1.11 YOU ARE (NOT) ALONE.
Scarred by the Second Impact, the Fourth Angel attacks Tokyo III and humanity's fate is left in the hands of Special Government Agency Nerv. Young Shinji Ikari is forced to pilot EVA-01. He and EVA-00 pilot Rei Ayanami are tasked to fight, but EVA-01 is damaged by the Sixth Angel. Misato Katsuragi draws up a plan to focus all of Japan's electricity into EVA-01's positron cannon to defeat the Angel.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Masayuki and Kazuya Tsurumaki, Screenwriter: Hideaki Anno
EVANGELION:2.22 YOU CAN (NOT) ADVANCE.
Mari Illustrious-Makinami pilots Provisional Unit-05 to defeat the excavated Third Angel. Asuka Langley-Shikinami and EVA-02 defeat the Seventh Angel. The Eighth Angel appears and attacks Nerv HQ. EVA-03 is taken over by the Ninth Angel during testing and Shinji deploys to stop it, but learns Asuka is aboard. Gendo switches EVA-01's controls over to the Dummy System and begins fighting EVA-03.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Masayuki and Kazuya Tsurumaki, Screenwriter: Hideaki Anno
EVANGELION:3.33 YOU CAN (NOT) REDO.
Shinji wakes after 14 years aboard the battleship AAA Wunder belonging to an anti-Nerv organization founded by former Nerv members. Shinji hears Rei's voice coming from EVA Mark.09, sent to rescue him, so he leaves Wunder and heads to Nerv. Kaworu Nagisa shows Shinji the transformed land. He learns that saving Rei triggered the Near Third Impact that caused the catastrophic damage to Earth.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Masayuki, Mahiro Maeda and Kazuya Tsurumaki, Screenwriter: Hideaki Anno
EVANGELION:3.0+1.01 THRICE UPON A TIME will join the thousands of TV shows and movies in the Prime Video catalogue, including award-winning and critically acclaimed global Amazon Originals like Borat Subsequent Moviefilm, Tom Clancy's Jack Ryan, The Boys, Hunters, Fleabag, and The Marvelous Mrs. Maisel. All this is available on Prime Video at no extra cost for Prime members. Prime members will be able to watch EVANGELION:3.0+1.01 THRICE UPON A TIME anywhere and anytime on the Prime Video app for smart TVs, mobile devices, Fire TV, Fire TV stick, Fire tablets, Apple TV, and stream online. In the Prime Video app, Prime members can download episodes on their mobile devices and tablets and watch anywhere offline.
Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005692/en/
Contact information
Press Contacts for Prime Video & Amazon Studios:
Arianne Rocchi: roccha@amazon.com
Ayumi Sakaguchi: ayusaka@amazon.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 14:42:00 EEST | Press release
Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429263104/en/ • Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bn • Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions • Transaction expected to close in
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 14:00:00 EEST | Press release
Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S. Marines. The Next Generation EW prototype is centered on the C5ISR Modular Open Suite of S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 14:00:00 EEST | Press release
Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means our partners can choose the networks that best fit their needs, while relying on Visa to provide
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom